Pentokey Organy India Ltd
BSE: 524210
₹ 30.85▲ 2.3 (+8.06%)28 Oct, 03:00 pm IST
- Market cap
- ₹ 21 Cr.
- P/E
- 71.7x
- P/B
- 1.94x
- 52-week range
- 28.49 – 57
- ROE
- 3%
- ROCE
- 2.6%
- Dividend yield
- 0%
- Debt / equity
- 0
- Sector
- Chemicals & Petrochemicals
- Industry
- Commodity Chemicals
- Listed on
- BSE
About
Pentokey Organy (India) Limited is an India-based company, which is engaged in the trading of pharmaceutical products. The Company operates through a single segment, which is Pharma.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Commodity Chemicals: 75 companies →Pentokey Organy India Ltd against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)71.7 against a typical 22.7: pricier than most peers (1st = cheapest).57th of 72
- Sales growth−100% against a typical +12.7% from a year earlier.64th of 65
- Profit growth−54.2% against a typical +13.6% from a year earlier.42nd of 49
- Share price, 3 months−15.2% against a typical −2.2%.52nd of 65
- Size₹ 20.7 Cr. market value against a typical ₹ 131.2 Cr. (1st = largest).54th of 69
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 1 | −2 | 2 | 0 |
| Expenses | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 1 | −2 | 2 | −0 |
| Operating Profit | 0 | −0 | −0 | −0 | −0 | −0 | −0 | 0 | 0 | −0 | −0 | 0 |
| OPM % | 12.1% | −233.3% | — | — | −18.2% | — | −3.3% | 8.7% | 3.1% | — | −10.1% | — |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0 | 0 | 0 |
| EPS in Rs | 0.57 | 0.06 | 0.08 | 0.08 | 0.18 | 0.06 | 0.1 | 0.77 | 0.22 | −0.46 | 0.32 | 0.35 |
Growth and returns
Compounded yearly rates over each period.
Compounded Sales Growth
- 10 Years
- −37%
- 5 Years
- —
- 3 Years
- −43%
- TTM
- −83%
Compounded Profit Growth
- 10 Years
- 7%
- 5 Years
- 25%
- 3 Years
- −57%
- TTM
- −61%
Stock Price CAGR
- 10 Years
- 9%
- 5 Years
- 10%
- 3 Years
- −7%
- TTM
- —
Return on Equity
- 10 Years
- −3%
- 5 Years
- 11%
- 3 Years
- 5%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
P/E 71.7xEPS (12 months) ₹ 0.43Median P/E 35x
P/E (times)EPS (₹)
Peers
Listed companies in the same business.
| Pentokey Organy India Ltd | ₹ 30.85 | ₹ 21 Cr. | 71.7x | 1.9x | 3% | — |
| Aurobindo Pharma | ₹ 1,569.30 | ₹ 90,294 Cr. | 27.7x | 2.6x | — | 10.6% |
| Neuland Laboratories | ₹ 18,882.05 | ₹ 24,132 Cr. | 80.2x | 15.8x | — | 21% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 28.2x | 5.1x | — | 28.6% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 36.8x | 5.8x | — | 15.5% |
| Unichem Laboratories | ₹ 470.00 | ₹ 3,309 Cr. | 51.3x | 1.4x | — | 13.2% |
Management
- Rajendra Babulal Gujrathi
- Chief Executive Officer, Chief Financial Officer
- Saurabh Mishra
- Compliance Officer, Company Secretary
Prices are delayed and for information only. Nothing on this page is investment advice.